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Betaine-homocysteine S-methyltransferase (BHMT) uses
betaine to catalyze the conversion of homocysteine (Hcy) to
methionine. There are common genetic polymorphisms in the
BHMT gene in humans that can alter its enzymatic activity. We
generated the first Bhmt/ mouse to model the functional
effects ofmutations that result in reduced BHMTactivity. Dele-
tion of Bhmt resulted in a 6-fold increase (p < 0.01) in hepatic
and an 8-fold increase (p < 0.01) in plasma total Hcy concentra-
tions. Deletion of Bhmt resulted in a 43% reduction in hepatic
S-adenosylmethionine (AdoMet) (p < 0.01) and a 3-fold
increase in hepatic S-adenosylhomocysteine (AdoHcy) (p <
0.01) concentrations, resulting in a 75% reduction in methyla-
tion potential (AdoMet:AdoHcy) (p < 0.01). Bhmt/ mice
accumulated betaine in most tissues, including a 21-fold
increase in the liver concentration compared with wild type
(WT) (p < 0.01). These mice had lower concentrations of cho-
line, phosphocholine, glycerophosphocholine, phosphatidyl-
choline, and sphingomyelin in several tissues. At 5 weeks of age,
Bhmt/ mice had 36% lower total hepatic phospholipid con-
centrations and a 6-fold increase in hepatic triacyglycerol con-
centrations compared with WT (p < 0.01), which was due to a
decrease in the secretion of very low density lipoproteins. At 1
year of age, 64% of Bhmt/ mice had visible hepatic tumors.
Histopathological analysis revealed that Bhmt/ mice devel-
oped hepatocellular carcinoma or carcinoma precursors. These
results indicate that BHMT has an important role in Hcy, cho-
line, and one-carbon homeostasis. A lack of Bhmt also affects
susceptibility to fatty liver and hepatocellular carcinoma. We
suggest that functional polymorphisms in BHMT that signifi-
cantly reduce activity may have similar effects in humans.
Betaine-homocysteine S-methyltransferase (BHMT)2 is a
zinc-dependent cytosolic enzyme that catalyzes the transfer of
a methyl group from betaine to homocysteine (Hcy) forming
dimethylglycine and methionine (Met) (Fig. 5). Humans have
common single nucleotide polymorphisms in the BHMT gene
that alter BHMT enzyme activity and function (1). A common
BHMT single nucleotide polymorphism rs3733890 (41% of NC
population has 1 variant allele, and 8% have 2 alleles (2)) was
associated with increased risk for having babies with neural
tube defects (3), decreased risk for developing cardiovascular
disease (4), and reduced risk for breast cancer-specific mortal-
ity (5). The epidemiological evidence suggests the importance
of single nucleotide polymorphisms in the gene. However, the
metabolic consequences of having null mutations of theBHMT
gene have not been thoroughly investigated. To directly inves-
tigate the role of BHMT in vivo, we generated and characterized
mice in which the gene encoding Bhmtwas deleted (Bhmt/).
BHMT activity is found at high levels in the liver and kidney,
and low levels in the brain, lenses, and other human tissues. In
rodents, high levels of BHMTactivity are only found in the liver
(6). Betaine, the methyl donor for BHMT, comes from either
dietary sources or from oxidation of choline (an irreversible
reaction) by choline dehydrogenase (CHDH). Alternatively,
choline can be used to form the phospholipid phosphatidylcho-
line (PtdCho) or the neurotransmitter acetylcholine (7). The
product of BHMT,methionine, is the precursor for S-adenosyl-
methionine (AdoMet), the major methyl donor for most bio-
logical methylations, including DNA and histone methylation,
the conversion of glycine tomethylglycine (catalyzed by glycine
methyltransferase (GNMT)), and the methylation of phos-
phatidylethanolamine (PtdEtn) to form PtdCho (catalyzed by
phosphatidylethanolamine N-methyltransferase (PEMT)).
The other substrate for BHMT is Hcy, a thiol-containing
amino acid, which, when elevated in plasma, is associated with
cardiovascular diseases, pregnancy complications, renal insuf-
ficiency, and cognitive impairment (8). Hcy is converted to
methionine by BHMT or by methionine synthase, the latter of
which usesmethyltetrahydrofolate (methyl-THF) as themethyl
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donor (supplied by methylenetetrahydrofolate reductase) (9).
Alternatively, Hcy is removed by the trans-sulfuration pathway,
forming cystathionine and cysteine catalyzed by the enzymes
cystathionine--synthase (CBS) and cystathionine--lyase
(CL), respectively (9). Both enzymes require vitamin B6; CBS
also requires AdoMet as the allosteric activator (9). All the
above pathways might be perturbed with the deletion of Bhmt.
Here, we report on the metabolic phenotype of the first Bhmt
knock-out mouse created.
EXPERIMENTAL PROCEDURES
Generation of Bhmt/Mice—The gene targeting vectorwas
designed to remove exons 6 and 7, the zinc-binding domains of
the gene (Fig. 1A). The targeting vector was constructed by
placing a MC1-neomycin (Neo) selectable marker flanked by 2
flippase (FLP) recognition target (FRT) sites and 1 locus of
X-over P1 (loxP) site 330 bp downstream of exon 7. A second
loxP site was introduced 240 bp upstream of exon 6. The
vector was electroporated into E14Tg2A embryonic stem cells.
Targeted cells were screened by PCR, confirmed by Southern
blot analysis, and injected into blastocysts derived from mouse
strain C57Bl/6 to create Bhmt transmitting chimeras. Neo
deleted mice were generated by crossing the transmitting chi-
meras with Flpe deleters (number 003800, Jackson Laboratory,
Bar Harbor, ME), which expressed Flpe recombinase that rec-
ognized FRT sites and deleted the Neo cassette. Bhmt knock-
out mice were generated by crossing the Neo deletedmice with
Cre deleters (number 003724, Jackson Laboratory), which
expressed Cre recombinase that recognized loxP sites and
deleted exons 6 and 7.Bhmt knock-outmice were continuously
backcrossed to C57Bl/6 mice. Generations F1 to F4 were used
in this study.
For all experiments,Bhmt/,Bhmt/, andBhmt/ litter-
mates born of Bhmt/ mating pairs were used to control the
mixed genetic background.Mice were genotyped by PCR using
TaKaRa Ex TaqDNA polymerase (TaKaRa Bio USA, Madison,
WI) and the following primer sequences: Bhmt/ forward,
5-GACTTTTAAAGAGTGGTGGTACATACCTTG-3,
Bhmt/ reverse, 5-TCTCTCTGCAGCCACATCTGAACT-
TGTCTG-3, Bhmt/ forward, 5-TTAACTCAACATCA-
CAACAACAGATTTCAG-3, Bhmt/ reverse, 5-TTGTC-
GACGGATCCATAACTTCGTATAAT-3. PCR conditions
were as follows: 94 °C for 2min; 40 cycles of 94 °C for 30 s, 64 °C
for 2 min, and 72 °C for 2 min; and 72 °C for 6 min. Bhmt/
PCR product was 1.6 kb in size, whereas Bhmt/ was 545 bp
(Fig. 1B). The animals were kept in a temperature-controlled
environment at 24 °C and exposed to a 12-h light and dark
cycle. All animals received AIN-76A pelleted diet with 1.1 g/kg
choline chloride (Dyets, Bethlehem, PA). The Institutional An-
imal Care and Use Committee of the University of North Car-
olina at Chapel Hill approved all experimental protocols.
Reproducibility, Viability, Body Weight, Body Length, and
Life Span—Pairs of Bhmt/, Bhmt/, and Bhmt/ parents
were bred to assess their reproductive potential. Sizes, genotype
distribution, and gender distribution of litters were recorded.
Bodyweights and lengths (nose to hip, nose to tail) ofBhmt/,
Bhmt/, andBhmt/miceweremeasured from age 3.5 to 20
weeks old using a scale and a ruler, respectively. Eleven
Bhmt/ and 14 Bhmt/ mice were maintained over the
course of a year to determine 1-year survival rates.
Western Blot and Enzymatic Assay—Mice were anesthetized
by inhalation of isoflurane (Hospira, Lake Forest, IL). Tissues
were harvested, weighted, snap frozen, pulverized under liquid
nitrogen, and stored at80 °C until used.Western blot analysis
of BHMT was performed in liver homogenate as previously
described (10). For all enzymatic assays, pulverized liver from
5-week-old mice were homogenized in buffer using a motor-
ized tissue homogenizer (Talboys Engineering Corporation,
Montrose, PA). BHMTactivitywasmeasured as the conversion
of [14C]betaine to [14C]methionine and [14C]dimethylglycine as
previously described (11). CHDH activity was measured as the
conversion of [14C]choline to [14C]betaine as previously
described (12) using high pressure liquid chromatography
(HPLC) on aVarian ProStarHPLC system (PS-210, Varian Inc.,
Palo Alto, CA) with a Pecosphere Silica column, 4.6  83 mm
(PerkinElmer Life Sciences) and a Berthold LB506C-1 radiode-
tector (Oak Ridge, TN). GNMT activity was measured as the
conversion of [3H]AdoMet to [3H]methylglycine using the
charcoal absorption method as previously described (13).
PEMT activity was measured as the conversion of [3H]AdoMet
to [3H]PtdCho as previously described (14, 15). Protein concen-
trations were measured using the Bradford Assay (16).
Choline and Homocysteine Metabolites—Tissues from
5-week-old animals were harvested as described above. Blood
was collected via cardiac puncture, and plasma was isolated by
centrifugation at 3,000  g for 5 min at room temperature. The
concentrations of choline metabolites were measured by liquid
chromatography-electrospray ionization-isotope dilutionmass
spectrometry as previously described (17). The concentration
of AdoMet and S-adenosylhomocysteine (AdoHcy) were mea-
sured using the Varian ProStar HPLC system as previously
described (18, 19) with anUltrasphereODS 5-mC18 column,
4.6  25 cm (number 235329, Fullerton, CA), and a UV-visible
detector (model 118, Gilson, Middleton,WI). Plasma total Hcy
(tHcy) and cysteine were measured after derivatizing 50 l of
plasmawith 7-fluorobenzofurazan-4-sulfonic acid. The deriva-
tized products were measured as previously described (20)
using the Varian ProStar HPLC system with a Microsorb-MV
5-m C18 column, 4.6 mm  25 cm (Varian) and a Prostar
model 360 fluorescence detector (Varian). Mercaptopropinyl-
glycine (10 M) was used as an internal standard. Hepatic tHcy,
cystathionine, methionine, cysteine, methylglycine, dimethyl-
glycine, and glycineweremeasured as previously described (21)
using capillary stable isotope dilution gas chromatography/
mass spectrometry (Hewlett-Packard Co., Palo Alto, CA).
Plasma total folate was measured using Lactobacillus casei
assay as previously described (22).
Clinical Analysis—Concentrations of plasma urea nitrogen
(BUN) and creatinine as well as activities of lactate dehydroge-
nase (LDH), alanine transaminase (ALT), and creatinine kinase
(CK) were measured using an automatic chemical analyzer
(Johnson and Johnson VT250, Rochester, NY) at the Animal
Clinical Chemistry and Gene Expression Facility, University of
North Carolina, Chapel Hill. Urine-specific gravity was mea-
sured using a refractometer (AO Instrument Co., Buffalo, NY)
at the Department of Laboratory Animal Medicine Veterinary
Deletion of Murine BHMT
OCTOBER 21, 2011 • VOLUME 286 • NUMBER 42 JOURNAL OF BIOLOGICAL CHEMISTRY 36259
and Technical Services Facility, UNC, Chapel Hill. Plasma tri-
acylglycerol (TAG), -hydroxybutyrate (Stanbio, Boerme, TX),
cholesterol, high density lipoprotein cholesterol (HDL-C),
nonesterified fatty acids (NEFA), and glucose (Wako, Rich-
mond, VA) were measured colorimetrically per the manufac-
turer’s instructions.
Triacylglycerol, Phospholipids, and Cholesterol—PtdCho,
PtdEtn, phosphatidylserine (PtdSer), and phosphatidylinositol
(PtdIns) were extracted from the liver of 5-week-oldmice using
the Bligh andDyermethod (23), and isolated by thin layer chro-
matography (TLC) (24). Concentrations were determined
using a phosphate assay (25). TAG was extracted from liver
samples using the Folch method (26) and measured colori-
metrically as described above.
In Vivo VLDL Secretion Rate—5-week-old animals were
fasted for 4 h. 500 mg/kg body weight of Triton WR1339 (as a
7.5% solution dissolved in PBS) was injected retro-orbitally.
Blood samples were taken using heparinized capillary tubes
retro-orbitally at 2, 30, 60, and 120 min after Triton WR1339
injection for TAGmeasurement as an indicator of the secretion
rate of the very low density lipoprotein (VLDL).
Tissue Histology—Liver was harvested and fixed in 4% para-
formaldehyde, 0.2% gluteraldehyde for 48 h. Liver was pro-
cessed, paraffin embedded, sectioned at 5 m, and stained with
hemotoxylin and eosin as previously described (27). For tumor
analysis, whole liver was sectioned serially, and multiple sec-
tions per sample were examined by 2 veterinary pathologists
from the Department of Laboratory Animal Medicine, UNC,
Chapel Hill. High resolution images were collected using a
Zeiss Axiovision A1 upright microscope.
-Glutamyltransferase 1 (GT1)—GT1 levels were deter-
mined using ELISA (Cedarlane, Burlington, NC). Frozen liver
samples from 1-year-old mice were homogenized in ice-cold
PBS at pH 7.0 containing 10% protease inhibitors (Sigma) using
an ultrasonic cell disruptor. The resulting suspension was cen-
trifuged and protein levels were determined by the Lowry
method (28). Equal amounts of proteins were loaded onto the
ELISA plate according to the manufacturer’s protocol. The
optical density was read at 450 nm on a Synergy 2 microplate
reader (Biotek, VT).
Statistics—Statistical differences were determined using
analysis of variance, Tukey-Kramer HSD, and Student’s t test
JMP version 6.0 (SAS Institute, Cary, NC) and reported as
mean  S.E.
RESULTS
Generation and Validation of Bhmt Knock-out Mice—
Bhmt/micewere generated using a cre/loxP system to delete
exons 6 and 7, which contain the zinc-binding domain essential
for BHMTactivity. Themouse genotypewas confirmed by PCR
using genomic DNA (Fig. 1B). Bhmt/ mice were also vali-
dated by assaying hepatic BHMTactivity (Fig. 1C) andWestern
blot (Fig. 1D). Deletion of 1 allele of Bhmt resulted in a 46%
reduction of activity, whereas deletion of both alleles resulted in
the absence of activity. BHMT protein is predominantly found
in mouse liver and was absent in Bhmt/ liver.
Bhmt Deletion Had No Effect on Reproductive Capacity or
Fetal Viability—Mating pairs of Bhmt/, Bhmt/, and
Bhmt/ mice produced offspring with similar litter size (7.5
pups/litter) with evenly distributed genders.Bhmt/ breeding
pairs were used to generate littermates of Bhmt/, Bhmt/,
andBhmt/mice for all experiments.Bhmt/ breeding pairs
produced offspring at the expectedMendelian ratio, with 24.5%
Bhmt/, 49.7% Bhmt/, and 25.8% Bhmt/ mice. The
Bhmt/ and Bhmt/ mice appeared healthy and lived for at
least 1 year.
Bhmt/ Mice Had Reduced Body Weight at Early Age—
Body length and weight of pups were monitored from 3.5 to 20
weeks of age. There was no significant difference in body length
FIGURE 1. Confirmation of Bhmt/ mice. A, Bhmt chimeric mice were gen-
erated using a gene targeting vector that removed exons 6 and 7 of the gene
as described under “Experimental Procedures.” loxP, locus of X-over P1; frt,
flippase recognition target; neo, neomycin cassette; flp, flippase recombina-
tion enzyme; cre, cyclization recombination enzyme. B, PCR analysis of
genomic DNA isolated from Bhmt/, Bhmt/, and Bhmt/ mice. The PCR
product of the WT allele was 1600 bp, whereas the knock-out allele was 545
bp. C, hepatic BHMT activity was measured using a radiometric assay in
Bhmt/ (black bar), Bhmt/ (hatched bar), and Bhmt/ (white bar) mice.
Data are presented as mean  S.E., n  4 – 8 per group. Different letters differ
significantly (p  0.01) by analysis of variance and Tukey-Kramer HSD tests.
D, BHMT protein in liver from Bhmt/ and Bhmt/ mice were probed by
Western blot analysis. The size of the BHMT protein is 45 kDa. E, body weights
of Bhmt/ (black square), Bhmt/ (gray square), and Bhmt/ (white square)
mice were measured using a scale from age 3.5 to 20 weeks old. Data are
presented as mean  S.E., n  10 –25 per group. *, p  0.05, different from
Bhmt/ by Student’s t test.
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among Bhmt/, Bhmt/, and Bhmt/ mice (data not
shown), and in body weight between Bhmt/ and Bhmt/
mice (Fig. 1E). Bhmt/ mice started with similar body weights
as did Bhmt/ mice at weaning (3.5 weeks), but gained less
weight between 5 and 9 weeks of age (p  0.05). The weight
difference did not persist after 9 weeks of age.
Bhmt Deletion Resulted in Altered Concentrations of Choline
and Its Metabolites—Bhmt is predominantly found in the liver,
however, complete deletion of Bhmt (Bhmt/) resulted in a
substantial increase in concentrations of betaine in liver (by
21-fold; p  0.001), kidney (by 5-fold; p  0.001), heart
(by 14-fold; p  0.001), brain (by 5-fold; p  0.001), muscle (by
12-fold; p  0.001), adipose (by 2-fold; p  0.001), lung (by
11-fold; p  0.001), and plasma (by 16-fold; p  0.001) com-
pared with Bhmt/ mice (Table 1). Deletion of Bhmt resulted
in reduced concentrations of choline in liver (by 82%; p 0.01),
kidney (by 38%; p 0.01), heart (by 42%; p 0.05), and adipose
(by 53%; p  0.01) compared with Bhmt/ mice. Deletion of
Bhmt resulted in reduced concentrations of PtdCho in liver (by
26%; p  0.01), kidney (by 21%; p  0.05), heart (by 25%; p 
0.01),muscle (by 25%; p 0.05), and plasma (by 31%; p 0.001)
compared with Bhmt/ mice. Deletion of Bhmt resulted in
reduced concentrations of phosphocholine (PCho) in liver (by
72%; p  0.01), heart (by 24%; p  0.05), muscle (by 65%; p 
0.001), and adipose (by 68%; p 0.01) comparedwithBhmt/
mice. Deletion of Bhmt resulted in reduced concentrations of
glycerophosphocholine (GPCho) in liver (p  0.01), kidney
(p  0.05), heart (p  0.001), adipose (p  0.05), and lung (p 
0.01), as well as reduced concentrations of sphingomyelin in
kidney (p  0.05) and heart (p  0.001) compared with
Bhmt/ mice. In testis, there was no change in any choline
metabolites in Bhmt/ mice. Deletion of 1 copy of Bhmt
(Bhmt/) resulted in cholinemetabolite concentrations in tis-
sues similar to those ofBhmt/mice (supplemental Table S1).
Bhmt Deletion Resulted in Altered Concentrations of Hcy,
AdoMet, AdoHcy, and Related Metabolites—In liver, complete
deletion ofBhmt resulted in a 43% decrease in AdoMet concen-
trations (p  0.01), and a 2.6-fold increase in AdoHcy concen-
trations (p  0.01), resulting in a 76% reduction in methylation
potential (AdoMet:AdoHcy) ratios (0.9  0.1 in Bhmt/ ver-
sus 3.6  0.2 in Bhmt/; p  0.01) (Table 2). Bhmt/ mice
also had reduced hepatic concentrations of dimethylglycine (by
95%; p  0.001), but had increased hepatic concentrations of
tHcy (by 6-fold; p  0.01) and methylglycine (by 2.6-fold; p 
0.05) compared with Bhmt/ mice. Hepatic cystathionine,
cysteine, methionine, and glycine did not differ among geno-
types. In plasma, deletion ofBhmt resulted in increased concen-
trations of tHcy (by 7.8-fold; p  0.001), decreased concentra-
tions of cysteine (by 48%; p  0.01), and decreased
concentrations of total folate (by 35%; p 0.01) compared with
plasma from Bhmt/ mice. Deletion of 1 copy of Bhmt
(Bhmt/) did not result in changes in hepatic methylation
potential, plasma tHcy, or plasma total folate compared with
Bhmt/ mice (supplemental Table S2). Bhmt/ had plasma
cysteine concentrations between those of Bhmt/ and
Bhmt/ mice.
TABLE 1
Deletion of Bhmt results in altered choline metabolites in various tissues
Tissues were harvested from 5-week-old Bhmt/ and Bhmt/ mice. Choline metabolites were extracted and quantified by liquid chromatography-electrospray ioniza-
tion-isotope dilution mass spectrometry. Data are presented as mean  S.E., n  5–10 animals/group.
Betaine Choline GPCho PCho PtdCho Sphingomyelin
Liver
Bhmt/ 1,321  254 154  36 1,730  554 294  67 15,897  1,200 1,018  131
Bhmt/ 27,314  2,001a 28  8b 266  38b 81  7b 11,686  305b 838  37
Kidney
Bhmt/ 1,151  91 779  60 15,608  1,475 853  37 16,088  1,025 3,373  277
Bhmt/ 5,424  505a 481  48b 10,948  672c 792  41 12,707  304c 2,685  74c
Heart
Bhmt/ 77  11 84  12 164  7 199  12 11,111  535 879  50
Bhmt/ 1,070  131a 49  6c 88  10a 151  14c 8,381  455b 583  44a
Brain
Bhmt/ 22  2 183  26 1,208  52 579  33 22,856  1,147 2,191  149
Bhmt/ 100  10a 174  15 1,120  57 502  9 21,020  271 1,834  52
Muscle
Bhmt/ 44  3 67  15 67  4 51  6 7,893  655 411  15
Bhmt/ 529  36a 28  3c 58  6 18  3a 5,942  238c 390  13
Adipose
Bhmt/ 142  25 73  12 802  223 90  6 2,500  217 156  14
Bhmt/ 284  18a 34  5b 246  79c 29  7c 2,288  271 144  18
Lung
Bhmt/ 206  17 198  24 3,586  348 551  26 14,693  344 2,389  65
Bhmt/ 2,237  123a 188  23 2,063  82a 465  42 14,437  192 2,387  47
Plasma
Bhmt/ 48  3 20  4 NDd ND 1,590  81 145  10
Bhmt/ 772  173a 13  2 ND ND 1,098  71a 114  77
Testis
Bhmt/ 2,014  312 298  51 809  26 3,831  270 5,760  387 886  74
Bhmt/ 2,018  111 241  10 565  47 3,706  234 5,942  233 954  38
a p  0.001 different from Bhmt/ by Student’s t test. Concentrations are expressed as nmol/g, except for plasma, which is nmol/ml.
b p  0.01, different from Bhmt/ by Students’ t test. Concentrations are expressed as nmol/g, except for plasma, which is nmol/ml.
c p  0.05, different from Bhmt/ by Students’ t test. Concentrations are expressed as nmol/g, except for plasma, which is nmol/ml.
d ND, not detected.
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Bhmt Deletion Resulted in Altered Activities of Enzymes
Involved in One-carbon Metabolism—Because Bhmt/ mice
(but not Bhmt/ mice) had altered one-carbon metabolites,
enzymes involved in one-carbonmetabolismweremeasured in
Bhmt/ and Bhmt/ mouse liver. Complete deletion of
Bhmt resulted in increased hepatic CHDH (by 1.33-fold; p 
0.05) and GNMT (by 1.13-fold; p  0.05) activities (Fig. 2).
Hepatic PEMT activity was not affected by Bhmt deletion.
Bhmt Deletion Resulted in Increased Hepatic Fat Accumula-
tion and Decreased Phospholipids—At 5 weeks of age, hepatic
TAG concentrations were 6.5-fold higher in Bhmt/ mice
than in Bhmt/ mice (p  0.05) (Fig. 3C). Bhmt/ mice had
similar hepatic TAG concentrations compared with that of
Bhmt/ mice (8.96  1.92 g/mg of tissue in Bhmt// ver-
sus 11.75 0.99g/mg of tissue inBhmt/). The difference in
hepatic steatosis betweenBhmt/ andBhmt/micewas eas-
ily visible at themicroscopic level (Fig. 3B). Hepatic and plasma
phospholipidsweremeasured inBhmt/ andBhmt/mouse
liver due to their involvement with hepatic lipid storage and
release. Bhmt/ mice had lower concentrations of phospho-
lipids in liver than Bhmt/ mice (Fig. 3A); with a 40% reduc-
tion in PtdCho (p  0.01), and a 60% reduction in PtdIns (p 
0.01). Bhmt/ mice also had a 31% reduction in plasma con-
centrations of PtdCho comparedwithBhmt/mice (p 0.01)
(Table 1). PtdEth concentrations in liver and plasma were the
same for both genotypes. Bhmt/ mice had a significantly
reduced VLDL secretion rate (Fig. 3D).
BhmtDeletionResulted inAlteredClinical Analyses—Plasma
alanine aminotransferase activity, a measure of liver damage,
wasmodestly increased inBhmt/mice (34.7 4.4 units/liter
in Bhmt/ versus 20.6  4.9 units/liter in Bhmt/; p  0.05)
(Table 3). Plasma BUN, creatinine, CK, and LDH, tests of kid-
ney and muscle function, showed no changes in the Bhmt/
mice. Urine-specific gravity was significantly reduced in
Bhmt/ mice (1.020  0.002 mg/dL in Bhmt/ versus
1.039  0.005 mg/dL in Bhmt/; p  0.01). Plasma TAG,
glucose, NEFA, and -hydroxybutyrate concentrations did not
differ between genotypes. Comparedwithwild type littermates,
Bhmt/ mice had significantly lower plasma total cholesterol
concentrations (by 45%, p  0.01) and HDL-C (by 38%, p 
0.01). Heterozygous mice had similar plasma ALT, BUN, cre-
atinine, LDH, CK, TAG, glucose, NEFA, and -hydroxybu-
tyrate concentrations compared with wild type mice (supple-
mental Table S2). Heterozygous mice had no change in plasma
FIGURE 2. Bhmt/ mice have altered activities of enzymes involved in
one-carbon metabolism. CHDH, GNMT, and PEMT activities were measured
in 5-week-old Bhmt/ (black bar) and Bhmt/ mice (white bar) mouse liver
using radiometric assays. Data are presented as mean  S.E., n  6 – 8 per
group. *, p  0.05, different from Bhmt/ by Student’s t test.
TABLE 2
Deletion of Bhmt results in reduced methylation potential and
increased homocyteine concentrations
Tissues were harvested from 5-week-old Bhmt/ and Bhmt/ mice. Hepatic
homocysteine metabolites were quantified by capillary stable isotope dilution gas
chromatography/mass spectrometry. Hepatic AdoMet, AdoHcy, and plasma total
homocysteine and cysteine were quantified by high pressure liquid chromatogra-
phy. Plasma total folate was quantified by a microbial (L. casei) assay. Data are
presented as mean  S.E., n  5–6 per group.
Organ Metabolites Bhmt/ Bhmt/
Liver AdoMet (nmol/g tissue) 76.4  3.7 43.5  5.7
a
AdoHcy (nmol/g tissue) 21.8  1.7 54.4  7.7a
AdoMet:AdoHcy 3.6  0.2 0.9  0.1a
tHomocysteine (nmol/g tissue) 4.2  0.3 26.5  5.5a
Methionine (nmol/g tissue) 223  26 242  23
Dimethylglycine (nmol/g tissue) 48.2  19.0 2.2  0.2a
Methylglycine (nmol/g tissue) 20.2  8.9 52.7  12.2b
Cystathionine (nmol/g tissue) 32.0  15.7 20.3  5.8
Cysteine (nmol/g tissue) 247  25 291  25
Glycine (nmol/g tissue) 1,659  128 1,561  135
Plasma tHomocysteine (M) 6.5  0.7 50.8  5.9a
Cysteine (M) 131.1  9.9 68.4  9.3a
tFolate (ng/ml) 81.7  6.4 52.8  5.1a
a p  0.01, different from Bhmt/ by Student’s t test.
b p  0.05, different from Bhmt/ by Student’s t test.
FIGURE 3. Bhmt/ mice have fatty liver and reduced hepatic phospho-
lipid concentrations. A, hepatic phospholipids of 5-week-old Bhmt/
(black bar) and Bhmt/ (white bar) mice were analyzed by a thin layer chro-
matography-phosphate assay method. Data are presented as mean  S.E.,
n  5 per group. *, p  0.01, different from Bhmt/ by Student’s t test.
B, morphology of liver from 5-week-old mice was shown by H&E staining at
100 magnification. Scale bar  50 m. C, hepatic TAG of 5-week-old
Bhmt/ (black bar) and Bhmt/ (white bar) mice was extracted and quanti-
tated by a colorimetric assay. Data are presented as mean  S.E., n  6 – 8 per
group. *, p  0.05, different from Bhmt/ by Student’s t test. D, VLDL secre-
tion rate of 5-week-old Bhmt/ (black square) and Bhmt/ (white square)
mice was determined by measuring the plasma TAG after lipoprotein lipase
inhibitor injection. Data are presented as mean  S.E., n  6 per group. *, p 
0.05, different from Bhmt/ by Student’s t test. PLs, phospholipids.
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cholesterol and HDL-C concentrations compared with
Bhmt/ mice.
Bhmt Deletion Resulted in Preneoplastic, Neoplastic, and
Regenerative Lesions in the Mouse Liver—Eleven Bhmt/ and
14 Bhmt/ mice were maintained over the course of a year to
determine 1-year survival rates. At time of sacrifice, 64% (9 of
14) of Bhmt/ mice and 0% (0 of 11) of Bhmt/ mice had
visible hepatic tumors (Fig. 4A). Tumors observed in Bhmt/
mice were solitary or multifocal, found in multiple liver lobes.
The average liverweight ofBhmt/micewas heavier than that
of Bhmt/ mice (6.22  2.11% BW in Bhmt/ versus 4.36 
0.26% BW in Bhmt/; p  0.001), attributable to tumor mass.
A subset of the liver samples (4 of 11 Bhmt/ livers, 6 of 9
Bhmt/ livers with tumors, and 4 of 5 Bhmt/ livers without
tumors) were serial-sectioned entirely, stained with H&E, and
send to two veterinary pathologists for diagnosis. Microscopic
analysis depicted a series of histological abnormalities from
preneoplastic lesions (acidophilic/eosinophilic cell foci) to
frank neoplasia visible only in the Bhmt/ mice (Table 4 and
FIGURE 4. Bhmt deletion results in liver tumors at 1 year of age. A, visible hepatic tumors in 1-year-old Bhmt/ male mice. The inspection of liver specimens
at 4 magnification revealed single or multiple nodules up to 8 mm in diameter. B, H&E images of tumor bearing livers at 400 magnification, showing
representative hepatocellular carcinoma and adenoma morphology. Scale bar, 50 m. 1, regenerative hyperplastic nodule containing streams of proliferative
oval and biliary cells; 2, hepatocellular adenoma (*, center of the nodule) well circumscribed with lobular structure absent, compressive borders, and eosino-
philic hepatocytes; 3, hepatocellular carcinoma represented by a large mass of abnormal vacuolated hepatocytes, containing poorly demarcated areas of
smaller hepatocytes with less vacuolization, amphophilic cytoplasm, and a streaming growth pattern (arrow); 4, hepatocellular carcinoma nodule of variably
sized hepatocytes exhibiting cytomegaly with hyaline droplets, small hepatocytes with streaming growth pattern, oval cell proliferation, Ito cell proliferation
between cords (unlabeled arrow), and infiltration of leukocytes.
TABLE 3
Deletion of Bhmt results in altered metabolic markers
Plasmawas collected from5-week-oldBhmt/ andBhmt/mice after 4 h fasting.
Concentrations of plasmaALT, BUN, creatinine, and activities of LDHandCKwere
quantitated by the Animal Clinical Chemistry and Gene Expression Facility, UNC,
Chapel Hill. Plasma triacylglycerol, cholesterol, HDL cholesterol, glucose, NEFA,
hydroxybutyrate were measured colorimetrically. Urine specific gravity was mea-
sured by the Department of Laboratory AnimalMedicine Veterinary and Technical
Services Facility, UNC, Chapel Hill. Data are presented as mean S.E., n 5–7 per
group.
Organ Clinical markers Bhmt/ Bhmt/
Plasma ALT (units/liter) 20.6  4.9 34.7  4.4
a
BUN (mg/dL) 12.5  0.8 13.0  1.8
Creatinine (mg/dL) 0.1 0.1
LDH (units/liter) 841  67 689  80
CK (units/liter) 741  147 511  147
Triacylglycerol (mg/dL) 60.9  7.7 47.2  7.9
Cholesterol (mg/dL) 57.8  4.3 31.6  4.3b
HDL-Cholesterol (mg/dL) 45.8  3.2 26.7  5.7b
Glucose (mg/dL) 292.5  33.2 226.0  15.9
NEFA (mM) 0.44  0.08 0.28  0.07
Hydroxybutyrate (mM) 0.39  0.08 0.29  0.03
Urine Specific gravity (mg/dL) 1.039  0.005 1.020  0.002b
a p  0.05, different from Bhmt/ by Student’s t test.
b p  0.01, different from Bhmt/ by Student’s t test.
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Fig. 4B). Hepatocellular adenomas were found in 30% (3 of 10)
of the analyzed Bhmt/ livers and none were found in the
control animals. These benign lesions were represented by sin-
gle or multiple nodules, sharply demarcated from the sur-
rounding tissues, with a mild to moderate compression border
and loss of lobular structure. Hepatocellular carcinomas (HCC)
were found in 50% (5 of 10) of the analyzed Bhmt/ livers.
HCC were represented by nodules of atypical, megalohepato-
cytes that were vacuolated or contained hyaline droplets. Indic-
ative of malignancy, these lesions were organized in cords that
were 5–6 cells wide, had poor or nonexisting interface with the
surrounding tissues, and compressed mildly the adjacent nor-
mal cords. The portal triads and sinusoids were poorly or non-
distinguishable in most of the nodules. Formation of heptocel-
lular adenomas and HCC in Bhmt/ mice were accompanied
by macro- and microvesicular steatosis, and stellate (Ito) cell
and/or oval (bililary) cell hyperplasia (Table 4). We did not
study Bhmt/ mouse survival or carcinogenesis.
Bhmt Deletion Resulted in Elevated  Glutamyltransferase 1
in Livers—GT1 is a highly sensitive marker of chronic liver
disease, neoplasia, and HCC (29). Bhmt/ mice had hepatic
GT1 concentrations 3.3-fold higher than that of the control
mice (0.815 0.049 ng/mg of tissue in Bhmt/ versus 0.245
0.085 ng/mg of tissue in Bhmt/; p  0.01).
Changes in Choline and One-carbon Metabolites at 5 Weeks
Persisted at 1-Year-old Bhmt/Mice—Choline deficiency and
reduced methylation potential have been hypothesized as
mechanisms underlying development of HCC. Compared with
wild type mice, Bhmt/ mice had a 91% reduction in hepatic
methylation potential (AdoMet:AdoHcy) compared with
Bhmt/mice (p 0.001) at 1 year (Table 5), whichwas greater
than the 76% reduction seen at 5 weeks of age (Table 2). The
reduced methylation potential was due to reduced hepatic
AdoMet (by 50%; p  0.01) and to elevated AdoHcy (by 5.5-
fold; p  0.001) concentrations in Bhmt/ mice compared
with Bhmt/ mice. Compared with wild type littermates,
Bhmt/ mice had a 30-fold increase in hepatic betaine, a 73%
reduction in GPCho, a 64% reduction in PCho, and an 18.8%
reduction in PtdCho concentrations. At 1 year old, Bhmt/
mice still had an elevated plasma tHcy concentration (by 6.9-
fold; p  0.01), but no longer had decreased plasma cysteine
concentration.
DISCUSSION
To our knowledge, this is the first report of the successful
creation of Bhmt/ mice. Deletion of the Bhmt gene resulted
in the complete loss of BHMT activity in liver, the organ where
nearly all of activity resides in mice. Heterozygous mice had
53% of the hepatic BHMT activity measured in Bhmt/, sug-
gesting that the Bhmt gene is biallelically expressed. Mating
pairs of Bhmt/, Bhmt/, and Bhmt/ produced offspring
with a normal number of pups and evenly distributed genders,
suggesting that BHMT is not essential for reproduction. This is
interesting because mice in which choline dehydrogenase
(Chdh; form betaine from choline, immediately upstream from
Bhmt in choline pathway, Fig. 5) was deleted are infertile (30).
Fetuses from heterozygous (Bhmt/) mating pairs were born
at the expected Mendelian ratio; they were viable and survived
to at least 1 year of age, suggesting that BHMT is not essential
for embryonic development or for the viability of mice.
Although a Bhmt knock-out mouse has not been previously
created, when S-(-carboxybutyl)-DL-homocysteine (CBHcy; a
potent and specific inhibitor of BHMT)was administered intra-
peritoneally to wild type mice (31) or fed to rats (32), it caused
an elevation of plasma Hcy concentrations and a reduction in
the hepatic AdoMet:AdoHcy ratio. Our current study confirms
the finding that inhibiting or ablating flux through BHMT
affects one carbonmetabolism. The changes are summarized in
Fig. 5. As expected,Bhmt/mice had significantly higher con-
TABLE 4
Pathology in livers from a subset of 1-year-old Bhmt/ and Bhmt/ mice
A subset of 1-year-oldBhmt/ (4 out of 11, none had visible tumors) andBhmt/mouse liver (6 out of 9 that had visible tumors, 4 out of 5 that did not have visible tumors)
were serial-sectioned, H&E stained, and send to 2 veterenary pathologists for diagnosis. Dots indicated the changes observed in a particular sample.





Bhmt/ ● ● ● ● ●
Bhmt/ ● ● ● ● ●
Bhmt/ ● ● ● ●
Bhmt/ ● ● ●
Bhmt/ ● ● ● ●
Bhmt/ ● ●





Metabolites in 1-year-old mouse tissues
Tissues were harvested from 1-year-old Bhmt/ and Bhmt/ mice. Hepatic
AdoMet, AdoHcy, and plasma homocysteine and cysteine were quantified by high
pressure liquid chromatography. Cholinemetaboliteswere extracted and quantified
by liquid chromatography-electrospray ionization-isotope dilutionmass spectrom-
etry. Data are presented as mean  S.E., n  8 per group.
Organ Metabolites Bhmt/ Bhmt/
Liver AdoMet (nmol/g tissue) 113.1  14.7 56.8  3.9
a
AdoHcy (nmol/g tissue) 31.9  5.3 176.3  22.1a
AdoMet:AdoHcy 4.05  0.65 0.35  0.03a
Betaine (nmol/g tissue) 1,158  330 34,976  2,700a
Choline (nmol/g tissue) 84  13 144  26
GPCho (nmol/g tissue) 803  121 218  21a
PC (nmol/g tissue) 674  90 243  59a
PtdCho (nmol/g tissue) 17,317  683 14,075  795a
Sphingomyelin (nmol/g tissue) 1,788  127 1,976  85
Plasma tHomocysteine (M) 5.5  0.7 37.7  8.6a
Cysteine (M) 150.8  17.4 134.6  23.1
a p  0.01, different from Bhmt/ by Student’s t test.
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centrations of the substrates for this enzyme (betaine and Hcy)
in various tissues as compared with Bhmt/ mice. Our data
show that the transsulfuration and methionine synthase path-
ways do not have the capacity to remove excess tHcy that accu-
mulates when BHMT is not present, indicating that BHMThas
a critical role in Hcy homeostasis. Bhmt/ mice also had a
significant reduction in hepatic dimethylglycine concentra-
tions, one of the products of BHMT. Methionine, the other
reaction product, was not affected by the gene deletion, proba-
bly because dietary methionine and protein stores of methio-
nine are so large that the loss of BHMT-catalyzed biosynthesis
does not alter overall concentrations of this amino acid. How-
ever, AdoMet concentration, which is formed from methio-
nine, was reduced in livers of Bhmt/ mice, whereas AdoHcy
concentrations were elevated. AdoMet is used by GNMT to
form methylglycine from glycine (33) (Fig. 5). Methylglycine is
also formed from dimethylglycine, the product of the BHMT
catalyzed reaction. Because Bhmt/ mice do not accumulate
dimethylglycine, the elevated methylglycine observed in
Bhmt/ mice likely comes from the action of GNMT. GNMT
is allosterically inhibited by methyl-THF (13), which serves as
the methyl donor for methionine synthase, a parallel pathway
to BHMT that catalyzes the conversion of Hcy to methionine
(9). It is possible that the Bhmt/ mice rely heavily on the use
of methyl-THF to form the neededmethionine. Hence, GNMT
is released from methyl-THF inhibition, resulting in increased
methylglycine, reduced AdoMet and increased AdoHcy con-
centrations that we observed. This hypothesis is supported by
elevated hepatic GNMT activity in Bhmt/ mice (Fig. 2), as
well as the reduction in plasma concentrations of total folate
(the predominant form contributing to plasma total folate is
methyl-THF) (Table 2). AdoHcy is cleaved by AdoHcy hydro-
lase, producing Hcy and adenosine. This reaction is reversible
and thermodynamically favors the synthesis of AdoHcy (34);
this should occur in the presence of the high tHcy concentra-
tions present in the Bhmt/ mice.
Despite high plasma tHcy concentrations, Bhmt/ mice
had significantly lower plasma cysteine concentrations; we
observed no differences in hepatic cysteine concentrations.
Normally, high Hcy would be expected to result in increased
cystathionine and cysteine concentrations. For example,
methylenetetrahydrofolate reductase-deficient mice had ele-
vated plasma Hcy, accompanied by elevated plasma cysteine
(35). Supplemental betaine has been shown to increase the
activity of liver CBS (36), thus the accumulation of this metab-
olite as well as tHcy in Bhmt/ mice would be expected to
increase concentrations of cysteine. However, AdoMet is an
allosteric activator of CBS (37), and we suggest that reduced
hepatic AdoMet concentrations inhibit the transsulfuration
pathway. The flux of cysteine from liver to plasma must be
rapid, perhaps explaining why plasma and not hepatic cysteine
concentrations are altered.
Deletion of Bhmt results in a substantial accumulation of
betaine in most tissues except testis. Betaine is either used as a
methyl donor (which is blocked by Bhmt deletion) or as an
osmolyte that regulates cellular volume and fluid balance. The
accumulation of betaine in Bhmt/ mice may affect osmoreg-
ulation. Tests of kidney function did not reveal anymalfunction
(Table 3). However, Bhmt/ mice had reduced urinary spe-
cific gravity compared with that of Bhmt/ mice (Table 3),
suggesting reduced reabsorption of water by the kidney tubule.
This finding is puzzling because high betaine should result in
increased reabsorption ofwater and increased urine osmolality.
Surprisingly, the deletion ofBhmt does not result in accumu-
lation of choline, the precursor of betaine. Choline is either
oxidized to form betaine by the enzyme CHDH or it is used to
formPtdCho. BecauseBhmt/mice cannot utilize betaine, we
expected to see product inhibition of CHDH resulting in
increased choline availability for use in PtdCho synthesis. We
observed the opposite, with lower choline and PtdCho concen-
trations in a number of tissues. Bhmt/ mice had elevated
hepatic expression of Chdh (data not shown) and hepatic
CHDH activity (Fig. 2), suggesting that this gene is induced by
some factor inBhmt/mice, possibly explaining increased use
of choline to formbetaine. The regulatorymechanisms for such
an effect are not known.
FIGURE 5. Changes in one-carbon metabolism due to Bhmt deletion. Deletion of Bhmt resulted in changes in the concentrations of the metabolites or
activities of enzymes involved in homocysteine and one-carbon metabolism in tissues.
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At 5 weeks of age, Bhmt/ mice developed a fatty liver, and
had elevated plasma ALT activity (a measure of hepatic dam-
age). The fatty liver is the result of decreased synthesis of
PtdCho, which is essential for the secretion of VLDL from liver
(38). These findings are consistent with the literature. Rodents
and humans fed a choline-deficient diet develop fatty liver (39,
40), and have elevated plasma ALT activity because choline
deficiency induces hepatocytes apoptosis (41). Consistent with
these observations in Bhmt/ mice, others have reported
administration of betaine or the induction of BHMT activity
prevents fatty liver inMthfr/ mice (35), in nonalcoholic fatty
liver (42), and in alcohol-induced fatty livers (43, 44) in rodents.
Together, these data suggest the importance of BHMT activity
inmodulating hepatic steatosis. In addition,Bhmt/mice had
reduced plasma total cholesterol and HDL-C. The role of Bhmt
deletion in cholesterol and lipoprotein homeostasis warrants
further studies.
At 1 year of age, 64% of Bhmt/ mice developed hepatic
tumors. Histopathology confirmed that these tumors were
either hepatocellular adenomas or carcinomas. Even those that
did not have visible tumors had a higher incidence of fat accu-
mulation, cellular alteration, and hyperplasia when compared
with Bhmt/ livers. Histological modifications were accom-
panied by elevation in GT1 levels, a highly sensitive marker of
HCC. In rodents, choline deficiency results in a higher inci-
dence of spontaneous hepatocellular carcinomas (45). Several
mechanisms are suggested for these carcinogenic effects. Cho-
line deficiency increases lipid peroxidation in the liver (46),
which is a source of free radicals in the nucleus that couldmod-
ify DNA and cause carcinogenesis. Choline deficiency perturbs
protein kinase C signaling, resulting in altered cell proliferation
signals and cell apoptosis and eventually in carcinogenesis (40).
Methyl deficiency may also mediate the mechanisms that
underlie the etiology of cancers. AdoMet levels control cell
growth, and a persistent decrease in AdoMet concentrations
leads to the development ofHCCas observed in themethionine
adenosyltranferase 1A knock-out mouse model (cannot make
AdoMet from Met) (48). Methyl deficiency may also alter epi-
genetic machinery by hypomethylating some genes but para-
doxically hypermethylating specific genes (tumor suppressor
genes) and consequently increasing the recruitment of methyl-
binding proteins to the CpG islands. Consequently, the expres-
sion of tumor suppressor genes responsible for DNA repair
(BRCA1, hMLH1), cell cycle regulation (p15, p16), carcinogen-
esis metabolism (GSTP1), hormonal response (RAR2), apo-
ptosis (DAPK, APAF-1), and cell adherence (CDH1, CDH3)
(49–51) are silenced, leading to tumor development. All the
above mechanisms are potentially the underlying causes of
HCC observed in Bhmt/ mice because these mice are essen-
tially choline and methyl-group deficient. We plan to investi-
gate each of these hypotheses in ongoing work in our
laboratory.
Hepatocellular carcinoma is the fifth most common type of
cancer worldwide (52). In mouse models harboring genetic
defects, HCC occurs spontaneously in a very limited number of
cases (47). For the first time, we present evidence that Bhmt
gene dysfunction links a metabolic defect to spontaneous neo-
plastic transformation in rodent livers. Bhmt/ mice model
marks the upper boundary for an effect of a lost-of-function
gene variant in humans. Our studies in the Bhmt/ mice sug-
gest that humans with lost-of-function mutation in the BHMT
gene may have important consequences, including hyperho-
mocysteinemia, altered choline metabolites, fatty liver, and
hepatocellular carcinomas. It would be interesting to explore
whether enhanced BHMT activity would reverse these
symptoms.
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